株式会社極東書店トップ商品一覧Norway's Pharmaceutical Revolution : Pursuing and Accomplishing Innovation in Nyegaard & Co., 1945-1997.

商品詳細

Norway's Pharmaceutical Revolution

Norway's Pharmaceutical Revolution : Pursuing and Accomplishing Innovation in Nyegaard & Co., 1945-1997.

・ISBN 978-0-19-286900-5 hard GB£ 99.00

¥31,363.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り

電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 978-0-19-196513-5

著者・編者Sogner, Knut,
出版社(Oxford U. Pr., UK)
出版年月2022.09
ページ数264 pp.
言語ENG
ニュース番号<680-366>

解説

The pharmaceutical revolution that gathered pace in the 1930s delivered a plethora of almost magical new drugs such as penicillin, streptomycin, cortisone, and the birth control pill. This revolution grew from academic-business relationships in five countries: USA, Germany, Great Britain, Switzerland, and France. Many other countries tried and failed to replicate this success, yet a handful of Scandinavia companies made important breakthroughs in a narrow band of specialities. This is the story of how one Norwegian company-- Nyegaard & Co. --achieved international success from the 1970s onwards with a breakthrough product facilitating X-ray pictures of the soft tissues of the body. The company succeeded by harnessing research skills and creating scientific and business alliances abroad, building its own momentum step by step: the corporation as entrepreneur. It thereby broke with the conventional way a national medical ecosystem facilitated the crucial scientific progress. This is a story both of personal initiatives and great organizational transformations in several stages. In the 1950s, Nyegaard & Co. was a small hierarchical home market-oriented generics company. By the end of the 1990s, it had developed into a fairly large and multinational hierarchical company, preoccupied as much with shareholder value as scientific progress. It has also become a company that no longer had the same ability to innovate as before and therefore became merged into another one.